CenterBook Partners LP Acquires 18,168 Shares of argenex SE (NASDAQ:ARGX)

CenterBook Partners LP raised its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 843.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,323 shares of the company's stock after buying an additional 18,168 shares during the period. argenex comprises 0.8% of CenterBook Partners LP's portfolio, making the stock its 25th biggest position. CenterBook Partners LP's holdings in argenex were worth $12,028,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Headlands Technologies LLC bought a new position in argenex in the 1st quarter valued at $4,779,000. Charles Schwab Investment Management Inc. raised its holdings in shares of argenex by 12.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 4,732 shares of the company's stock valued at $2,801,000 after buying an additional 518 shares during the last quarter. Legacy Capital Group California Inc. acquired a new position in argenex during the 1st quarter worth about $264,000. Intrust Bank NA grew its holdings in argenex by 14.0% during the 1st quarter. Intrust Bank NA now owns 710 shares of the company's stock worth $420,000 after acquiring an additional 87 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new stake in argenex in the 1st quarter valued at about $1,040,000. Institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ARGX shares. Oppenheimer raised their price target on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Guggenheim lowered their target price on argenex from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Morgan Stanley started coverage on argenex in a research report on Thursday, July 3rd. They set an "overweight" rating and a $700.00 target price for the company. Citigroup reiterated a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Finally, Robert W. Baird upgraded argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective for the company in a research report on Tuesday, May 13th. Nineteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $728.06.

argenex Stock Down 1.6%

Shares of ARGX traded down $9.38 during trading hours on Thursday, reaching $568.54. The stock had a trading volume of 279,217 shares, compared to its average volume of 333,368. The firm has a 50-day moving average of $563.56 and a 200 day moving average of $600.69. The company has a market cap of $34.79 billion, a P/E ratio of 35.22, a P/E/G ratio of 1.01 and a beta of 0.37. argenex SE has a 52 week low of $457.42 and a 52 week high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%. As a group, equities analysts expect that argenex SE will post 3.13 earnings per share for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.